Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.

  title={Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.},
  author={Takaki Toda and Erik Eliasson and Birgitta Ask and Nobuo Inotsume and Anders Rane},
  journal={Basic \& clinical pharmacology \& toxicology},
  volume={105 5},
  • T. Toda, E. Eliasson, A. Rane
  • Published 1 November 2009
  • Biology, Chemistry, Medicine
  • Basic & clinical pharmacology & toxicology
Fluvastatin has been considered to be metabolised to 5-hydroxy fluvastatin (M-2), 6-hydroxy fluvastatin (M-3) and N-desisopropyl fluvastatin (M-5) in human liver microsomes by primarily CYP2C9. To elucidate the contribution of different CYP enzymes on fluvastatin metabolism, we examined the effect of CYP inhibitors and CYP2C-specific monoclonal antibodies on the formation of fluvastatin metabolites in human liver microsomes. Human liver microsomes were incubated with fluvastatin with or without… 

Figures and Tables from this paper

Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
The prediction results showed that the interaction between telmisartan and fluvastatin via CYP enzymes were negligible in clinical situations, and predictions of drug-drug interactions (DDI) were important for the safety of combination therapies with statins.
Dietary Flavonoids Modulate CYP2C to Improve Drug Oral Bioavailability and Their Qualitative/Quantitative Structure–Activity Relationship
Tamarixetin significantly inhibited CYP2C activity in vitro and in vivo and could improve the therapeutic efficacy of drugs with low bioavailability, according to the present study.
Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population
In hypercholesterolemic patients, LDL-C serum concentration was decreased more significantly in fluvastatin-treated subjects bearing the CYP2C9*1/*3 genotype compared to CYP1/*1 genotype, however, due to rare occurrence of some CYP genotypes, it was impossible to report a definitive positive genotype-fluvASTatin effect association.
Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.
The total plasma cholesterol level is an important determinant for the plasma 4β-hydroxycholesterol level, and was shown to be unchanged in all three treatment groups.
Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers
Although in vitro studies indicated that EGCG and brewed green tea produce significant inhibitory effects on CYP2C9 activity, the concomitant administration of green tea and fluvastatin in healthy volunteers did not influence the pharmacokinetics of fluVastatin.
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
A comprehensive overview of the available pharmacological and clinical evidence on this potential drug–drug interaction (DDI) is provided, and canagliflozin appears to be the SGLT2 inhibitor with the highest interaction potential.
Beneficial Effects of Quercetin on Obesity and Diabetes
Good perspectives have been opened for Quercetin, according to the results obtained either in cell cultures or in animal models, but further studies are needed to better characterize the mechanisms of action underlying the beneficial effects of this flavonoid on these pathologies.
Formulation and Optimization of Fluvastatin Loaded Self-emulsifying Drug Delivery Systems
Introduction: The current research is aimed at formulating and evaluating fluvastatin self-nanoemulsifying drug delivery system (SNEDDS). Materials and Methods: Fluvastatin SNEDDS formulated using


The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Several human cytochrome P-450 enzymes metabolize fluvastatin with CYP2C9 contributing 50-80%.
The xenobiotic inhibitor profile of cytochrome P4502C8.
AIMS To investigate inhibition of recombinant CYP2C8 by: (i) prototypic CYP isoform selective inhibitors (ii) imidazole/triazole antifungal agents (known inhibitors of CYP), and (iii) certain CYP3A
Clinical Pharmacokinetics of Fluvastatin
Fluvastatin is relatively hydrophilic, compared with the semisynthetic HMG-CoA reductase inhibitors, and, therefore, it is extensively absorbed from the gastrointestinal tract, and does not appear to have a significant effect on other CYP isoenzymes or P-glycoprotein-mediated transport in vivo.
Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450
  • Y. SaiR. Dai M. Shou
  • Biology, Chemistry
    Xenobiotica; the fate of foreign compounds in biological systems
  • 2000
The results indicate that sulphaphenazole, quinidine and α-naphthoflavone are selective inhibitors of CYP2C9, CyP2D6 and CYP1A isoforms on the basis of the IC50, which are much lower than those of other P450 isoforms (> 10-fold).
Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism
YP-engineered cells or their microsomes (‘supersomes’) have made the identification of the CYPs involved in the metabolism of a drug candidate straightforward and easier.
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
No relationship was found between the CYP2C9 genotype and the 4′-hydroxylation of diclofenac either in vivo or in vitro.
Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
Nine chemical inhibitors were selected based on literature data and were examined for their specificity toward cytochrome P450-mediated reactions in human liver microsomes and troleandomycin proved to be the most specific for testosterone 6 beta-hydroxylation.
Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
The effects of sulfaphenazole, 1, on typical activities catalyzed by human cytochromes P450 of the 1A, 3A, and 2C subfamilies expressed in yeast were studied and a model for the binding of 1 in the CYP 2C9 active site is proposed.
Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models
This review evaluates the major human hepatic drug‐metabolizing CYP enzymes and their clinically relevant substrates, inhibitors, and inducers and discusses the molecular bases and clinical implications of genetic polymorphisms that affect the CYPs.